Companies Summit Therapeutics Inc.
Summit Therapeutics (SMMT): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Summit Therapeutics Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $0FY2023
- $158,613FY2024
- $172,376FY2025
CEO total pay was $172,376 in fiscal 2025, up from $158,613 in fiscal 2024.
FY2025: salary $0 · bonus $0 · stock awards $0 · option awards $0
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Manmeet Soni | $616,500 | $388,395 | $0 | $248,101,887 | $0 | $0 | $21,000 | $249,127,782 |
| Chief Operating Officer, Chief Financial Officer and Director | ||||||||
| Mahkam Zanganeh | 616,500 | 388,395 | 0 | 245,021,384 | 0 | 0 | 21,000 | 246,047,279 |
| Co-Chief Executive Officer, President and Director | ||||||||
| Robert Duggan | 0 | 0 | 0 | 0 | 0 | 0 | 172,376 | 172,376 |
| Co-Chief Executive Officer and Chairman of the Board of Directors | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Manmeet Soni | $249,127,782 | $4,772,489 | $23,613,339 | ↑ +244,355,293 |
| Mahkam Zanganeh | 246,047,279 | 1,161,021 | 20,562,924 | ↑ +244,886,258 |
| Robert Duggan | 172,376 | 158,613 | 0 | ↑ +13,763 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
We seek to ensure that the total compensation paid to our NEOs is reasonable and competitive. Compensation of our NEOs is structured around the achievement of individual performance, annual Company objectives and key results (“OKRs”) and long-term business objectives.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Mahkam Zanganeh | Option | 133,300 | 1.29 | — |
| Mahkam Zanganeh | Option | 346,580 | 1.06 | — |
| Manmeet Soni | Option | 825,000 | 3.85 | — |
| Mahkam Zanganeh | Option | 3,196,053 | 1.68 | — |
| Manmeet Soni | Option | 3,732,400 | 1.68 | — |
| Mahkam Zanganeh | Option | 5,994,099 | 1.68 | — |
| Manmeet Soni | Option | 7,000,000 | 1.68 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Kenneth A. ClarkIndependent · Lead Independent Director · Compensation (Chair) · Nominating and Corporate Governance (Chair) | $0 | $0 | $835,697 | — | $0 | $835,697 |
| Robert BoothIndependent · Audit · Nominating and Corporate Governance | 0 | 0 | 672,773 | — | 0 | 672,773 |
| Yu (Michelle) XiaNot independent | 0 | 0 | 649,996 | — | 0 | 649,996 |
| Jeff HuberIndependent · Audit (Chair) | 86,600 | 0 | 562,586 | — | 0 | 649,186 |
| Alessandra CesanoIndependent · Nominating and Corporate Governance | 28,200 | 0 | 611,981 | — | 0 | 640,181 |
| Mostafa RonaghiIndependent · Audit · Compensation | 62,900 | 0 | 562,586 | — | 0 | 625,486 |
| Manmeet SoniEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Robert W. DugganEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Mahkam ZanganehEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $49,900 |
|---|---|
| Annual equity retainer | $35,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 36,700 / 13,000 / 13,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $177,700 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $177,700 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Summit Therapeutics as a peer
Companies that benchmark against SMMT
7 companies name SMMT as a compensation peer
The list of companies that name SMMT as a peer is temporarily unavailable — recheck shortly.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Summit Therapeutics Inc. | 2025 | Robert Duggan | $0 | $0 | $0 | $0 | $172,376 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-10 | 622,624,328 | 24,445,791 | 101,383 | 96.22% | Passed |
| 2025 | 2025-06-12 | 607,320,353 | 16,607,648 | 177,556 | 97.34% | Passed |
| 2024 | 2024-06-14 | 604,242,482 | 15,872,371 | 879,801 | 97.44% | Passed |
| 2021 | 2021-06-16 | 61,902,912 | 65,335 | 97,479 | 99.89% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-10 | 96.22%a |
| 2025 | 2025-06-12 | 97.34%b |
| 2024 | 2024-06-14 | 97.44%c |
a. Approved under the standard stated in the filing — “If you ABSTAIN from voting on this proposal, your abstention will not be counted as a vote cast on Proposal 3 and will have no effect on the outcome of the proposal.”.
b. Approved under the standard stated in the filing — “If you ABSTAIN from voting on this proposal, your abstention will not be counted as a vote cast on Proposal 3 and will have no effect on the outcome of the proposal.”.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 489 : 1 |
|---|---|
| CEO total compensation | $246,047,279 |
| Median employee compensation | $503,340 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Robert W. Duggan | Director | 2026-06-04 | A | 100,000 | $15 | $1,460,000 | Common, indirect | Form 4 ↗ |
| Manmeet Soni | Director | 2026-06-04 | A | 25,000 | 14 | 360,750 | Common | Form 4 ↗ |
| Manmeet Soni | Director | 2026-06-04 | A | 25,000 | 14 | 361,500 | Common | Form 4 ↗ |
| Mahkam Zanganeh | Director | 2026-06-04 | A | 100,000 | 15 | 1,460,000 | Common, indirect | Form 4 ↗ |
| Mahkam Zanganeh | Director | 2026-06-12 | A | 3,810,000 | 13 | 49,987,200 | Common, indirect | Form 4 ↗ |
| Robert W. Duggan | Director | 2026-06-12 | A | 3,810,000 | 13 | 49,987,200 | Common | Form 4 ↗ |
| Bhaskar Anand | Chief Accounting Officer | 2026-10-08 | A | 100,000 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (26 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Manmeet Soni. DEF 14A, filed 2026-04-17. Section “Executive Compensation”. As printed: 249,127,782. View filing ↗
- Section 01, Mahkam Zanganeh. DEF 14A, filed 2026-04-17. Section “Executive Compensation” · page 44. As printed: 246,047,279. View filing ↗
- Section 01, Robert Duggan. DEF 14A, filed 2026-04-17. Section “Executive Compensation”. As printed: 172,376. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-17. Section “CEO Pay Ratio”. As printed: 489 : 1. View filing ↗
- Section 08, Kenneth A. Clark. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 835,697. View filing ↗
- Section 08, Robert Booth. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 672,773. View filing ↗
- Section 08, Yu (Michelle) Xia. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 649,996. View filing ↗
- Section 08, Jeff Huber. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 649,186. View filing ↗
- Section 08, Alessandra Cesano. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 640,181. View filing ↗
- Section 08, Mostafa Ronaghi. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 625,486. View filing ↗
- Section 08, Manmeet Soni. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Robert W. Duggan. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Mahkam Zanganeh. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Robert W. Duggan 2026-06-04. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Manmeet Soni 2026-06-04. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Manmeet Soni 2026-06-04. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mahkam Zanganeh 2026-06-04. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mahkam Zanganeh 2026-06-12. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert W. Duggan 2026-06-12. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bhaskar Anand 2026-10-08. Form 4, filed 2026-10-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-12. Item 5.07 · say-on-pay result. As reported: 96.22% (votes for as printed: 622,624,328). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-17. Item 5.07 · say-on-pay result. As reported: 97.34% (votes for as printed: 607,320,353). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-17. Item 5.07 · say-on-pay result. As reported: 97.44% (votes for as printed: 604,242,482). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 177,700 + equity 0 + all other 0 = 177,700, summed across the director compensation table rows.
- Summit Therapeutics Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Summit Therapeutics Inc.'s own proxy. As printed: 172,376. View filing ↗